BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it has revised its first quarter 2022 financial and operating results Financial markets will publish the close of trading in the US on Tuesday, May 10, 2022.
Conference call/webcast information:
| Date: | Tuesday, May 10, 2022 |
| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
| dial-in number: | 855-779-9075 |
| International dial-in: | 631-485-4866 |
| Conference ID: | 2263884 |
The webcast will also be streamed live on the Investors section of the Xenon website at investor.xenon-pharma.com. When available, webcasts will be posted for replay after the event. The above dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to improve the lives of patients suffering from neurological diseases. We are advancing a novel product pipeline of neurological therapies to address areas of high unmet medical need, with a focus on epilepsy. Visit www.xenon-pharma.com for more information.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owners.
Investor/media contact:
Beverly Regts
Xenon Pharmaceuticals Inc.
Telephone: 604.484.3353
Email: [email protected]
Comments are closed.